Avalyn Pharma Inc. Payments to Acquire Marketable Securities
Avalyn Pharma Inc. (AVLN) reported Payments to Acquire Marketable Securities of $134.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-12
- Avalyn Pharma Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $134.83M, a 110.07% increase year-over-year.
- Avalyn Pharma Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Avalyn Pharma Inc. payments to acquire marketable securities for the quarter ending 2025-06-30 was $64.19M.
- Avalyn Pharma Inc. payments to acquire marketable securities for the quarter ending 2025-03-31 was $2.87M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month |
|---|---|---|
| 2026-06-30 | $134.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $134.83M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-06-03 | |
| 2025-06-30 | $64.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $67.06M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $2.87M 10-Q · filed 2026-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |